NEW YORK (GenomeWeb News) – Proteome Sciences today announced a contract with Japanese drug firm Eisai to provide biomarker services for Alzheimer's disease.
Under the terms of the deal, Proteome Sciences, based in Surrey, UK, will measure candidate biomarkers for AD using its AD-TMT-SRM assay set on human samples, it said in a statement.
Financial and other terms of the deal were not disclosed.